Journal•ISSN: 0030-2414
Oncology
Karger Publishers
About: Oncology is an academic journal published by Karger Publishers. The journal publishes majorly in the area(s): Cancer & Breast cancer. It has an ISSN identifier of 0030-2414. Over the lifetime, 9281 publications have been published receiving 198923 citations.
Topics: Cancer, Breast cancer, Chemotherapy, Radiation therapy, Lung cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: PgR positivity and lymph node metastases significantly correlated with late recurrence means it is important to evaluate appropriate measures such as treatment period and treatment regimen for hormone-sensitive patients.
Abstract: Background: Breast cancer is associated with a relatively good prognosis. Prognostic factors examined to date are related to early recurrence while those related
2,038 citations
TL;DR: The production of VEGF and other growth factors by the tumor results in the ‘angiogenic switch’, where new vasculature is formed in and around the tumor, allowing it to grow exponentially.
Abstract: Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein with a molecular weight of approximately 45 kDa. It is the key mediator of angiogenesis (the formation of new blood vessels), an
1,410 citations
Journal Article•
TL;DR: The contribution of reactive oxygen and nitrogen intermediates, prostaglandins, and inflammatory cytokines to carcinogenesis is discussed, which can lead to novel approaches to the prevention and treatment of cancer.
Abstract: A substantial body of evidence supports the conclusion that chronic inflammation can predispose an individual to cancer, as demonstrated by the association between chronic inflammatory bowel diseases and the increased risk of colon carcinoma. Chronic inflammation is caused by a variety of factors, including bacterial, viral, and parasitic infections, chemical irritants, and nondigestible particles. The longer the inflammation persists, the higher the risk of associated carcinogenesis. This review describes some of the underlying causes of the association between chronic inflammation and cancer. Inflammatory mediators contribute to neoplasia by inducing proneoplastic mutations, adaptive responses, resistance to apoptosis, and environmental changes such as stimulation of angiogenesis. All these changes confer a survival advantage to a susceptible cell. In this article, we discuss the contribution of reactive oxygen and nitrogen intermediates, prostaglandins, and inflammatory cytokines to carcinogenesis. A thorough understanding of the molecular basis of inflammation-associated neoplasia and progression can lead to novel approaches to the prevention and treatment of cancer.
799 citations
TL;DR: The research suggests that the antitumor efficacy of HER2-specific antibodies such as Herceptin® relates to their ability to direct HER2 to a Cbl- dependent endocytosis and degradation pathway.
Abstract: Human epidermal growth factor receptor-2 (HER2/erbB-2) belongs to a family of four transmembrane receptors involved in signal transduction pathways that regulate cell growth and differentiation. Overe
703 citations
TL;DR: expression of miR-21 correlated with CRC clinical stage, and a high expression was associated with lymph node positivity and the development of distant metastases in CRC patients, suggesting possible roles of microRNAs in CRC.
Abstract: Objectives: Development and metastases of colorectal cancer (CRC) are characterized by multiple genetic alterations MicroRNAs (miRNAs) are endogenously expressed regulatory noncoding RNAs Previous, mainly preclinical studies showed altered expression levels of several miRNAs in CRC Methods: In our study, the expression levels of miR-21, miR-31, miR-143 and miR-145 in 29 primary colorectal carcinomas and 6 non-tumor adjacent tissue specimens were examined by real-time polymerase chain reaction miRNA expression levels were also correlated with commonly used clinicopath-ologic features of CRC Results: Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 00001) and miR-31 (p = 00006) were upregulated, and miR-143 (p = 0011) and miR-145 (p = 0003) were downregulated in tumors For the first time, a high expression of miR-21 was associated with lymph node positivity (p = 0025) and the development of distant metastases (p = 0009) in CRC patients Thus, expression of miR-21 correlated with CRC clinical stage (p = 0032) Furthermore, tumors >50 mm in maximal tumor diameter were characterized by lower expression of miR-143 (p = 0006) and miR-145 (p = 0003) We found no correlation between analyzed miRNAs and serum levels of carcinoembryonic antigen Conclusion: Our results suggest possible roles of miR-21, miR-31, miR-143 and miR-145 in CRC
696 citations